Bing

SEARCH HISTORY

or a 14.1% annualized rate of return (at Stock Options Channel we call this the YieldBoost). START SLIDESHOW: Top YieldBoost Puts of the S&P 500 » Selling a put does not give an investor access to CYTK's …
The Street · 15 hours ago
The stock has a 50-day moving average of $6.38 and a 200-day moving average of $6.88. The company’s market cap is $252.43 million. Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Thursday, April 30th. The biopharmaceutical …
Ticker Report · 7/1/2015
Cytokinetics (NASDAQ:CYTK), a company whose shares are moving quickly ... based on a current level of $6.52 and analysts' average consensus price target of $13.80. The stock should discover initial support at its 50-day moving average (MA) of $6.43 ...
Financial News Network Online · ByMallory Stone · 6/30/2015
More from Bing News
People suffering from the disease eventually lose voluntary muscle control. Roughly 25,000 Americans have ALS. CYTK stock closed at $12.99 per share on Thursday.
Investor Place · ByChristopher Freeburn · 4/25/2014
Cytokinetics, Incorporated (CYTK) was a big mover last session, as its shares surged over 26% on the day. The surge came on solid volume too with far more shares changing hands than in a normal session. This reverses the trend for the company since …
Yahoo Finance · 2/10/2014
Cytokinetics (NASDAQ:CYTK)‘s stock had its “buy” rating restated by research analysts at MLV & Co. in a report released on Friday. They currently have a $9.00 price objective on the stock. MLV & Co.’s price objective would suggest a potential ...
sleekmoney.com · 5/3/2015
Cytokinetics, Incorporated ( CYTK) was a big mover last session, as the company saw its shares rise over 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent …
NASDAQ · 11/5/2014
Small cap ALS and stem cell stock Brainstorm Cell Therapeutics Inc (NASDAQ ... the performance of stem cell stocks or ALS stocks like Cytokinetics, Inc (NASDAQ: CYTK), Neuralstem, Inc (NYSEMKT: CUR) and NeoStem Inc (NASDAQ: NBS). However …
Smallcap Network · ByJohn Udovich · 1/2/2015
Throughout this year, Cytokinetics’ (NASDAQ:CYTK) shares have been moving between $1.12 and $2.96. During this time, the stock has been knocked down more than 60% and the recent turbulence in the market has not helped much either. This is a …
Seeking Alpha · 7/20/2011
Cytokinetics (NASDAQ:CYTK) Director L Patrick Gage purchased 10,000 shares of Cytokinetics stock in a transaction that occurred on Wednesday, May 6th. The shares were purchased at an average price of $5.71 per share, with a total value of $57,100.00.
wkrb13.com · 5/9/2015